Compare Stocks → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:AORTSE:COSNASDAQ:SBTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORiShares Core Growth Allocation ETF$53.81-0.3%$54.64$47.56▼$55.74$1.98B0.62260,033 shs125,250 shsCOSCanadian Oil SandsC$0.00C$5.61▼C$13.87N/AN/A2.19 million shsN/ASBTXSilverback Therapeutics$8.09-2.1%$8.82$2.80▼$8.97$291.71M0.6337,931 shs534,599 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORiShares Core Growth Allocation ETF-0.30%+0.62%-2.76%+1.09%+8.34%SBTXSilverback Therapeutics-2.06%-10.71%-19.10%+24.08%+24.46%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ACOSCanadian Oil SandsN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORiShares Core Growth Allocation ETF0.00N/AN/AN/ACOSCanadian Oil Sands3.00BuyC$0.52∞ UpsideSBTXSilverback TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest AOR, SBTX, COS, and ANR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024COSCanadian Oil SandsFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$0.52(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/ACOSCanadian Oil SandsN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORiShares Core Growth Allocation ETFN/AN/A17.21∞N/AN/AN/AN/AN/ACOSCanadian Oil SandsN/AN/A0.00N/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORiShares Core Growth Allocation ETF$1.082.01%N/AN/AN/ACOSCanadian Oil SandsN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORiShares Core Growth Allocation ETFN/AN/AN/ACOSCanadian Oil SandsN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORiShares Core Growth Allocation ETFN/ACOSCanadian Oil SandsN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipAORiShares Core Growth Allocation ETFN/ACOSCanadian Oil SandsN/ASBTXSilverback Therapeutics34.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAORiShares Core Growth Allocation ETFN/A36.80 millionN/ANot OptionableCOSCanadian Oil Sands147,000N/AN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableAOR, SBTX, COS, and ANR HeadlinesSourceHeadlineSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2.8%americanbankingnews.com - April 25 at 1:48 AMSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2%marketbeat.com - April 3 at 2:15 AMARS Pharmaceuticals Inc (SPRY)uk.investing.com - May 11 at 1:32 PMWild Isleswwf.org.uk - March 12 at 9:31 AMA look back at RNA Therapeutics – day onepharmaphorum.com - February 24 at 12:35 AMSPRY ARS Pharmaceuticals, Inc.seekingalpha.com - January 24 at 8:04 PMARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger247wallst.com - November 22 at 6:29 AMDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeuticsnasdaq.com - November 18 at 8:19 PMARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxisfinance.yahoo.com - November 10 at 6:41 PMARS Pharmaceuticals Closes Merger with Silverback Therapeuticsfinance.yahoo.com - November 8 at 5:59 PMSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactionsmarkets.businessinsider.com - October 28 at 8:15 AMFDA accepts ARS Pharma’s NDA for Neffythepharmaletter.com - October 24 at 10:29 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIkentuckytoday.com - October 23 at 7:22 PMSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxisfinance.yahoo.com - October 21 at 7:59 AMIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?aaii.com - October 19 at 11:52 AMSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNbakersfield.com - October 12 at 11:07 PMINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTmarkets.businessinsider.com - September 17 at 5:10 AMSBTX Silverback Therapeutics, Inc.seekingalpha.com - September 15 at 10:58 PMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTmarkets.businessinsider.com - September 6 at 11:53 AMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYmarkets.businessinsider.com - August 23 at 6:32 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXapnews.com - August 17 at 12:02 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXapnews.com - August 11 at 1:33 AMSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigationsmorningstar.com - July 30 at 7:00 AMINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYapnews.com - July 28 at 2:21 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesThe Bottom is in For Tesla: Read This Before Buying the BounceApril 24, 2024 8:45 AMView The Bottom is in For Tesla: Read This Before Buying the BounceIs Estée Lauder on the Verge Of a Massive Comeback?April 4, 2024 11:10 AMView Is Estée Lauder on the Verge Of a Massive Comeback?DexCom Stock Gains from GLP-1 Diabetic UsersApril 2, 2024 7:16 AMView DexCom Stock Gains from GLP-1 Diabetic UsersInstitutions Think This Consumer Stock Could Break HigherApril 8, 2024 9:40 AMView Institutions Think This Consumer Stock Could Break HigherCostco vs. Walmart: Revenue Comparison of Two Retail GiantsApril 15, 2024 11:39 AMView Costco vs. Walmart: Revenue Comparison of Two Retail GiantsAll Headlines Company DescriptionsiShares Core Growth Allocation ETFNYSEARCA:AORiShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.Canadian Oil SandsTSE:COSCanadian Oil Sands Limited is a Canada-based investment company. The Company owns a 36.74% interest in the Syncrude Joint Venture (Syncrude), a producer of low sulphur, light, synthetic crude oil (SCO). Syncrude is involved in the mining and upgrading of bitumen from oil sands near Fort McMurray in northern Alberta. The Syncrude Project is comprised of open-pit oil sands mines, utilities plants, bitumen extraction plants and an upgrading complex that processes bitumen into SCO. Syncrude's leases are located in the Athabasca oil sands deposit. Syncrude produces SCO by mining oil sands, extracting the bitumen from the sands, upgrading the recovered bitumen into lighter oil fractions and combining those fractions into a single SCO product.Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.